Skip to main content
. 2020 May 25;10:8629. doi: 10.1038/s41598-020-65043-8

Figure 5.

Figure 5

Treatment monitoring using the RISK6 signature in the IMPRESS cohort. (a) Comparison of RISK6 signature scores in HIV-infected TB cases (irrespective of treatment outcome) from the IMPRESS cohort at baseline, month 2 after treatment initiation, at treatment completion (EoRx) and 6–8 months after treatment completion (Post Rx). Horizontal lines depict medians, the boxes the IQR and the whiskers the range. Violin plots depict the density of data points. (b) ROC curves depicting performance of RISK6 for discriminating between baseline (pre-treatment) samples and samples collected at month 2 after treatment initiation, at treatment completion (EoRx) and 6–8 months after treatment completion (Post Rx). Shaded areas depict the 95% CI. The boxes in the top left corner represent the optimal (solid line) and minimum (dotted line) criteria set out in the target product profile for a screening/triage test for TB. (c) ROC curve depicting performance of RISK6, measured at 2 months on TB treatment, for discriminating between TB cases who converted their sputum to negative by 2 months (early converters) and those who converted after 2 months. (d) Comparison of RISK6 signature scores in IMPRESS participants stratified by detectable (>400 RNA copies/mL plasma) vs. undetectable plasma HIV load (<400 RNA copies/mL plasma). Horizontal lines depict medians, the boxes the IQR and the whiskers the range. Violin plots depict the density of data points. The effect size is the relative difference in median plasma viral load and the p-value was calculated using Mann-Whitney U test.